Filing Flows

Filing Flows › Companies › Strata Critical Medical › Cash flow

Strata Critical Medical cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$9.1M in Q3 2026 · $806K over twelve months

Operating cash flow$9.5M
Capital spending−$400K
Free cash flow+$9.1M
Cash conversion cycle27 days

Analysis

In Q3 2026, Strata Critical Medical generated $9.5M of operating cash flow and spent $400K on capital projects, leaving free cash flow of $9.1M. That is $49.3M more than in Q3 2025 (−$40.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was $10.7M; the largest uses were acquisitions ($37.2M), taxes on employees’ shares ($10.7M), capital spending ($9.9M); besides operations, cash came from other investing ($59.7M), shares issued ($113K); the cash balance rose by $12.4M.

Operating cash flow was $9.5M against net income of −$7.6M. The largest differences: depreciation & amortization +$7.3M, stock-based pay +$5.0M, receivables +$1.4M.

Its cash conversion cycle was 27 days (receivables 54 + inventory 0 − payables 26).

Free cash flow

Strata Critical Medical: free cash flow by quarterStrata Critical Medical: free cash flow by quarter−$6.3MQ4 2024−$2.9MQ1 2025−$5.3MQ2 2025−$40.2MQ3 2025−$10.2MQ4 2025−$1.3MQ1 2026$3.2MQ2 2026$9.1MQ3 2026
Operating cash flow less capital spending.
Strata Critical Medical: operating cash flow against capital spendingStrata Critical Medical: operating cash flow against capital spendingOperating cash flowCapital spending−$1.8M$4.6MQ4 2024−$246K$2.6MQ1 2025−$3.1M$2.2MQ2 2025−$37.3M$2.9MQ3 2025−$8.3M$1.8MQ4 2025$3.9M$5.2MQ1 2026$5.7M$2.5MQ2 2026$9.5M$400KQ3 2026
Latest (Q3 2026): Operating cash flow $9.5M, Capital spending $400K.

Capital allocation, year by year

Strata Critical Medical: where the cash came from (up) and went (down), by fiscal yearStrata Critical Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2020: Operating cash flow −$794KFY2020FY2022: Operating cash flow −$37.1MFY2022: Shares issued $87KFY2022: Capital spending −$730KFY2022: Acquisitions −$48.1M$87KFY2022FY2023: Operating cash flow −$32.3MFY2023: Shares issued $70KFY2023: Asset sales $138KFY2023: Capital spending −$2.1M$208KFY2023FY2024: Operating cash flow −$2.5MFY2024: Shares issued $168KFY2024: Asset sales $13KFY2024: Capital spending −$30.9MFY2024: Acquisitions −$2.2MFY2024: Buybacks −$244K$181KFY2024FY2025: Operating cash flow −$48.9MFY2025: Shares issued $193KFY2025: Capital spending −$9.6MFY2025: Acquisitions −$66.5M$193KFY2025
Over these 5 years operating cash flow totalled −$122M; the largest uses were operating cash flow ($122M) and acquisitions ($117M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$41.6M
Debtnone
Net cash$41.6M

Strata Critical Medical funds itself: free cash flow was $806K over the last twelve months, with $41.6M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Strata Critical Medical: sources (+) and uses (−) of cash, Q3 2026Strata Critical Medical: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)−$18.8MOther investing$14.9MOperating cash flow$9.5MTaxes on employees’ shares−$4.1MAcquisitions−$995KCapital spending−$400KOther financing−$17KShares issued$4K
Strata Critical Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Strata Critical Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$59.7MAcquisitions−$37.2MCash drawn (+) / kept (−)−$12.4MOperating cash flow$10.7MTaxes on employees’ shares−$10.7MCapital spending−$9.9MOther financing−$355KShares issued$113K

From profit to cash

Strata Critical Medical: net income to operating cash flow, Q3 2026Strata Critical Medical: net income to operating cash flow, Q3 2026Net income−$7.6MDepreciation & amortization$7.3MStock-based pay$5.0MGains on investments$1.3MReceivables$1.4MPayables$54KDeferred revenue−$12KPrepaid and other assets−$1.1MOperating cash flow$9.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202654—2627
Q2 202652—3022
Q1 202653—3320
Q4 202553—4113
Q3 202561—4913
Q2 202551—3020
Q1 202553—3122
Q4 202456—3719

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$9.5M−$400K−$995K$4K−$18.8M$9.1M
Q2 2026$5.7M−$2.5M—$3K$42.4M$3.2M
Q1 2026$3.9M−$5.2M—$52K−$27.8M−$1.3M
Q4 2025−$8.3M−$1.8M−$1.4M$54K−$8.2M−$10.2M
Q3 2025−$37.3M−$2.9M−$65.2M$65K$37.3M−$40.2M
Q2 2025−$3.1M−$2.2M—$14K−$24.6M−$5.3M
Q1 2025−$246K−$2.6M—$60K−$16.0M−$2.9M
Q4 2024−$1.8M−$4.6M—$44K$1.8M−$6.3M

Strata Critical Medical: income statement and cash flow

Strata Critical Medical, Q3 2026: revenue $74.1M (+50% year over year), operating margin -5.2%. The chart follows the revenue to costs, profit and cash.

Strata Critical Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.